Current Obstetrics and Gynecology Reports

, Volume 4, Issue 4, pp 220–233 | Cite as

HPV Vaccination: Current Global Status

  • Julia M. L. Brotherton
  • Paul J. N. Bloem
Management of HPV and Associated Cervical Lesions (L Denny, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Management of HPV and Associated Cervical Lesions


Human papillomavirus vaccines have been in use in populations for nearly 10 years. They now have an established record of high efficacy, effectiveness and safety in the prevention of vaccine-type HPV infection and disease, including genital warts and pre-cancers. Their considerable immunogenicity has resulted in trials to study two-dose schedules, which are now approved by WHO and in many countries for use in young adolescents at a spacing of at least 6 months between doses. As of mid 2015, 65 countries have HPV vaccines on their national immunisation schedule, with variable coverage achieved to date.


Human papillomavirus HPV vaccine Immunisation Vaccine coverage 


Compliance with Ethics Guidelines

Conflict of Interest

Julia M. L. Brotherton declares to have been an investigator on investigator designed unrestricted epidemiological research grants partially funded through bioCSL but has received no personal financial benefits.

Paul J. N. Bloem declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12–23.CrossRefPubMedGoogle Scholar
  2. 2.•
    Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80. Excellent summary of the impacts of HPV vaccination to date.CrossRefPubMedGoogle Scholar
  3. 3.
    Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination. March 12, 2014. Available at: ment_HPV_12_Mar_2014.pdf?ua=1
  4. 4.
    Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother. 2012;8(3):390–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Nygard M KS, Dillner J et al. Long-term effectiveness and immunogenicity of Gardasil in the Nordic countries. Abstract OC 6–3, Eurogin 2013, Florence, Italy 3–6 November (pg 201 abstract book). 2013.Google Scholar
  6. 6.
    Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100–10.CrossRefPubMedGoogle Scholar
  7. 7.
    Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4- year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.CrossRefPubMedGoogle Scholar
  8. 8.
    Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer prevention research (Philadelphia). Cancer Prevent Res (Philadelphia, PA). 2009;2(10):868–78.CrossRefGoogle Scholar
  9. 9.
    Giuliano AR, Palefsky JM, Goldstone S, Moreira Jr ED, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401–11.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Palefsky JM, Giuliano AR, Goldstone S, Moreira Jr ED, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. Eng J Med. 2011;365(17):1576–85.CrossRefGoogle Scholar
  11. 11.
    Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 2011;12(9):862–70.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE. 2013;8(7):e68329.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Apter D, Wheeler CM, Paavonen J, Castellsague X, Garland SM, Skinner SR, et al. Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomised, double-blind PATRICIA trial. Clin Vaccin Immunol. 2015;22(4):361–73.CrossRefGoogle Scholar
  14. 14.
    Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, et al. Reduced prevalence of vulvar HPV 16/18 infection among women who received the HPV 16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial. J Infect Dis. 2014;210(12):1890–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez- Avila M, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ (Clin Res Ed). 2010;341:c3493.CrossRefGoogle Scholar
  16. 16.
    Ault KA, Future II, Group S. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693–702.CrossRefPubMedGoogle Scholar
  18. 18.
    Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Eng J Med. 2007;356(19):1928–43.CrossRefGoogle Scholar
  19. 19.
    Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28–37.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmeron J, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384(9961):2213–27.CrossRefPubMedGoogle Scholar
  21. 21.•
    Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ (Clin Res ed). 2012;344:e1401. Analysis of trial data suggesting a benefit of vaccination for secondary prevention of new infection and disease in women with previous high grade disease.CrossRefGoogle Scholar
  22. 22.
    Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110(11):2804–11.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013;32(1):26–32.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208(3):385–93.CrossRefPubMedGoogle Scholar
  25. 25.
    Dunne EF, Naleway A, Smith N, Crane B, Weinmann S, Braxton J, et al. Reduction in HPV vaccine type prevalence among young women screened for cervical cancer in an integrated health care delivery system, United States 2007, 2012–2013. J Infect Dis. 2015.Google Scholar
  26. 26.
    Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross- sectional study. Lancet Infect Dis. 2014;14(10):958–66.CrossRefPubMedGoogle Scholar
  27. 27.
    Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ (Clin Res Ed). 2013;346:f2032.Google Scholar
  28. 28.
    Sando N, Kofoed K, Zachariae C, Fouchard J. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women—an ecological study. Acta Dermato-Venereol. 2014;94(3):288–92.CrossRefGoogle Scholar
  29. 29.
    Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11(1):227.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case–control study nested within a population based screening programme in Australia. BMJ (Clin Res Ed). 2014;348:g1458.Google Scholar
  31. 31.
    Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824–30.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia—nationwide follow-up of young Danish women. J Natl Cancer Inst Nat Cancer Inst. 2014;106(3):djt460.CrossRefGoogle Scholar
  33. 33.
    Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol. 2014;32(5):438–43.CrossRefPubMedGoogle Scholar
  34. 34.
    Brotherton JM, Saville AM, May CL, Chappell G, Gertig DM. Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes Control. 2015;26(6):953–4.CrossRefPubMedGoogle Scholar
  35. 35.
    Cervical screening in Australia 2012–2013. Australian Institute of Health and Welfare. Cancer Series No. 93 Cat. No. CAN 91.Google Scholar
  36. 36.•
    Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5:F123–38. Comprehensive summary of the HPV vaccine trials.CrossRefPubMedGoogle Scholar
  37. 37.
    Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134(3):e657–65.CrossRefPubMedGoogle Scholar
  38. 38.
    Brown D, Muller M, Sehr P, Pawlita M, Seitz H, Rubio I, et al. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. Vaccine. 2014;32(44):5880–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin. 2011;7(2):230–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV- 6/11/16/18 vaccine: follow-up from months 12–24 in a phase III randomized study of healthy women aged 18–45 years. Human Vaccines. 2011;7:1343–58.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross- protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. Hum Vacc Immunother. 2014;10(5).Google Scholar
  43. 43.•
    Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802. Trial demonstrating equivalent immunogenicity of two doses of quadrivalent HPV vaccine in young adolescents.CrossRefPubMedGoogle Scholar
  44. 44.
    Human papillomavirus vaccines: WHO position paper, October 2014, WER. Available at:
  45. 45.•
    Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modelling predictions from a randomized study. Hum Vaccin Immunother. 2015; 15:0. Study showing sustained immunogenicity of two doses of bivalent HPV vaccine in adolescents and predicting durable protection.Google Scholar
  46. 46.•
    Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV- 16/18 AS04 adjuvanted vaccine: combined analysis of data from the Cosa Rica vaccine trial and the PATRICIA Trial. Lancet Oncol. 2015;16(7):775–86. Analysis suggesting equivalent efficacy to three doses from one or two doses of bivalent HPV vaccine.CrossRefPubMedGoogle Scholar
  47. 47.
    Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis. 2015;211(9):1373–5.CrossRefPubMedGoogle Scholar
  48. 48.
    Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014;311(6):597–603.CrossRefPubMedGoogle Scholar
  49. 49.
    Brotherton JML, Malloy M, Budd A, Saville M, Drennan K, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Research. in press, 2015.Google Scholar
  50. 50.
    Petrosky E, Bocchini Jr JA, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR. 2015;64(11):300–4.PubMedGoogle Scholar
  51. 51.•
    Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9- valent HPV vaccine against infection and intraepithelial neoplasia in women. N Eng J Med. 2015;372(8):711–23. RCT analysis for the nine valent HPV vaccine showing equivalent immunogenicity as quadrivalent vaccine against types 6/11/16/18 and high efficacy against types 31/33/45/52/58.CrossRefGoogle Scholar
  52. 52.
    Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1997–2008.CrossRefPubMedGoogle Scholar
  53. 53.
    de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.CrossRefPubMedGoogle Scholar
  54. 54.
    Callreus T, Svanstrom H, Nielsen NM, Poulsen S, Valentiner-Branth P, Hviid A. Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events. Vaccine. 2009;27(22):2954–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis. 2007;26(11):979–84.CrossRefGoogle Scholar
  56. 56.
    Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15(1):116–9.CrossRefPubMedGoogle Scholar
  57. 57.•
    Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ (Clin Res Ed). 2013;347:f5906. Robust whole of population safety study establishing no increase in autoimmune, neurological or thromboembolic disease in HPV vaccine recipients.Google Scholar
  58. 58.
    Scheller NM, Svanstrom H, Pasternak B, Arnheim-Dahlstrom L, Sundstrom K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313(1):54–61.CrossRefPubMedGoogle Scholar
  59. 59.
    Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Inter Med. 2012;271(2):193–203.CrossRefGoogle Scholar
  60. 60.
    Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46):8279–84.CrossRefPubMedGoogle Scholar
  61. 61.
    Grimaldi-Bensouda L, Guillemot D, Godeau B, Benichou J, Lebrun-Frenay C, Papeix C, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Internal Med. 2014;275(4):398–408.CrossRefPubMedGoogle Scholar
  62. 62.
    Goss MA, Lievano F, Seminack MM, Dana A. No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy: 6-year pregnancy registry data. Obstet & Gynecol. 2014;123 Suppl 1:93S.CrossRefGoogle Scholar
  63. 63.
    Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet & Gynecol. 2009;114(6):1170–8.CrossRefGoogle Scholar
  64. 64.
    Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet & Gynecol. 2009;114(6):1179–88.CrossRefGoogle Scholar
  65. 65.
    Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI, et al. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006–2013. Vaccine. 2015;33(4):519–22.CrossRefPubMedGoogle Scholar
  66. 66.
    Angelo MG, David MP, Zima J, Baril L, Dubin G, Arellano F, et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf. 2014;23(5):466–79.PubMedCentralCrossRefPubMedGoogle Scholar
  67. 67.
    Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, et al. An overview of quadrivalent human papillomavirus vaccine safety—2006 to 2015. Pediat Infect Dis. 2015.Google Scholar
  68. 68.
    Gardasil (quadrivalent human papillomavirus vaccine), update 2. Australian Government, Department of Health, Therapeutic Goods Administration. Available at:
  69. 69.
    Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571.CrossRefPubMedGoogle Scholar
  70. 70.
    O’Dowd A. Teenager who died after having HPV vaccine had a malignant chest tumour. BMJ (Clin Res Ed). 2009;339:b4032.CrossRefGoogle Scholar
  71. 71.
    Buttery JP, Madin S, Crawford NW, Elia S, La Vincente S, Hanieh S, et al. Mass psychogenic response to human papillomavirus vaccination. Med J Aust. 2008;189(5):261–2.PubMedGoogle Scholar
  72. 72.
    EMA to further clarify safety profile of human papillomavirus (HPV) vaccines. Press release, European Medicines Agency, Science Medicines Health, 13 July, 2015. Available at:
  73. 73.
    Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction—the first five years. Vaccine. 2012;30 Suppl 5:F139–48.CrossRefPubMedGoogle Scholar
  74. 74.
    WHO/UNICEF joint reporting form, 1 July 2015. Available from:
  75. 75.
    Eight in 10 adolescent girls in the Americas have access to HPV vaccine, following its introduction in Brazil. Washington DC, March 20, 2014 (PAHO/WHO) Available at: id=9394:el-80-de-las-ninas-adolescentes-de-las-americas-tendra-acceso- a-la-vacuna-contra-el-vph-tras-haberse-introducido-en-brasil- &catid=740:news-press-releases&Itemid=1926&lang=en 2014.
  76. 76.
    Hanson CM, Eckert L, Bloem P, Cernuschi T. Gavi HPV programs: application to implementation. Vaccines. 2015;3:408–19.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    Rubin R. Why the "no-brainer" HPV vaccine is being ignored. JAMA. 2015;313(15):1502–4.CrossRefPubMedGoogle Scholar
  78. 78.
    LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull WHO. 2011;89(11):821–30B.PubMedCentralPubMedGoogle Scholar
  79. 79.
    Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Pub Health. 2012;12:370.CrossRefGoogle Scholar
  80. 80.
    Ladner J, Besson MH, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009–2013. BMC Public Health. 2014;14:670.PubMedCentralCrossRefPubMedGoogle Scholar
  81. 81.
    van den Ent MM, Brown DW, Hoekstra EJ, Christie A, Cochi SL. Measles mortality reduction contributes substantially to reduction of all cause mortality among children less than five years of age, 1990–2008. J Infect Dis. 2011;204 Suppl 1:S18–23.PubMedGoogle Scholar
  82. 82.
    Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbe M, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet. 2014;383(9911):40–7.CrossRefPubMedGoogle Scholar
  83. 83.
    Vermandere H, Naanyu V, Mabeya H, Vanden Broeck D, Michielsen K, Degomme O. Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya. PLoS ONE. 2014;9(10):e109353.PubMedCentralCrossRefPubMedGoogle Scholar
  84. 84.
    Bartolini RM, Winkler JL, Penny ME, LaMontagne DS. Parental acceptance of HPV vaccine in Peru: a decision framework. PLoS ONE. 2012;7(10):e48017.PubMedCentralCrossRefPubMedGoogle Scholar
  85. 85.
    Dorji T, Tshomo U, Phuntsho S, Tamang TD, Tshokey T, Baussano I, et al. Introduction of a national HPV vaccination program into Bhutan. Vaccine. 2015;33(31):3726–30.CrossRefPubMedGoogle Scholar
  86. 86.
    Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme. Bull WHO. 2012;90(8):623–8.PubMedCentralPubMedGoogle Scholar
  87. 87.
    McRee AL, Gilkey MB, Dempsey AF. HPV vaccine hesitancy: findings from a statewide survey of health care providers. J Pediatr Health Care. 2014;28(6):541–9.PubMedCentralCrossRefPubMedGoogle Scholar
  88. 88.
    Verger P, Fressard L, Collange F, Gautier A, Jestin C, Launay O, et al. Vaccine hesitancy among general practitioners and its determinants during controversies: a national cross-sectional survey in France. EBioMedicine, in press. 2015.Google Scholar
  89. 89.
  90. 90.
    Galagan SR, Paul P, Menezes L, LaMontagne DS. Influences on parental acceptance of HPV vaccination in demonstration projects in Uganda and Vietnam. Vaccine. 2013;31(30):3072–8.CrossRefPubMedGoogle Scholar
  91. 91.
    Remes P, Selestine V, Changalucha J, Ross DA, Wight D, de Sanjose S, et al. A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine. 2012;30(36):5363–7.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.National HPV Vaccination Program RegisterEast MelbourneAustralia
  2. 2.School of Population and Global HealthThe University of MelbourneAustralia
  3. 3.Expanded Programme on ImmunizationWorld Health Organization1211 GenevaSwitzerland

Personalised recommendations